ACR 2020 – Predictors of Response in Nr‑axSpA Treated with Certolizumab Pegol: The C-axSpAnd Study

touchCONGRESS for touchIMMUNOLOGY Walter Maksymowych (University of Alberta, Alberta, Canada) talks to touchIMMUNOLOGY about the results of the C-axSpAnd Study (NCT02552212). This 52-week placebo-controlled study aimed to identify demographic or baseline characteristics of patients with nr-axSpA that could be predictive of achieving a clinical response to treatment with certolizumab pegol. The abstract entitled ‘Predictors of Response in Patients with Non-Radiographic Axial Spondyloarthritis Receiving Certolizumab Pegol in the C-axSpAnd Study’ was presented at ACR Convergence 2020, 5-9 November.